Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 1/2 1Phase 1 1

Status

Terminated 2Withdrawn 1

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Sarcoma 1Other solid neoplasm 1Gastrointestinal 1

Conditions

Stomach Neoplasms 1Solid Tumor 1Sarcoma, Clear Cell 1Adenocarcinoma Of Esophagus 1

Interventions

Carboplatin 273Paclitaxel 267Gemcitabine 244Bevacizumab 226Cisplatin 218pembrolizumab 214Docetaxel 210Pemetrexed 162Capecitabine 148Fluorouracil 129Oxaliplatin 121Cyclophosphamide 121Nivolumab 112Dexamethasone 100Trastuzumab 89Leucovorin 87Cetuximab 85Rituximab 83Irinotecan 82Injections 81Erlotinib Hydrochloride 70Prednisone 68Doxorubicin 68Temozolomide 67atezolizumab 65Bortezomib 65Ipilimumab 64Fulvestrant 59Radiotherapy 54Drug Therapy 51

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 2 × INDUSTRY × AMG 337 × Clear all
NCT03132155 2024-05-24

QUILT-3.031: AMG 337 in Subjects With Advanced or Metastatic Clear Cell Sarcoma

NantPharma, LLC

Phase 2 Terminated
8 enrolled 10 charts
Sarcoma

Sarcoma, Clear Cell

NCT03147976 2019-08-28

QUILT-3.036: AMG 337 in Subjects With Advanced or Metastatic Solid Tumors

NantPharma, LLC

Phase 2 Withdrawn
Other solid neoplasm

Solid Tumor

NCT02016534 2017-07-02

Phase 2 Study of AMG 337 in MET Amplified Gastric/Esophageal Adenocarcinoma or Other Solid Tumors

Amgen

Phase 2 Terminated
60 enrolled
Gastrointestinal

Adenocarcinoma Of Esophagus, Stomach Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡